About Careers MedBlog Contact us

Novartis Announces FDA Approval for Rare Pancreatic Cancer Drug

by Kathy Jones on May 7, 2011 at 5:12 PM
Font : A-A+

 Novartis Announces FDA Approval for Rare Pancreatic Cancer Drug

Swiss pharmaceutical giant Novartis has announced that its cancer drug Afinitor has received approval from the US Food and Drug Administration to be used in the treatment of a rare pancreatic cancer.

Afinitor had earlier received unanimous backing by a US advisory panel to use the drug in treating advanced pancreatic neuroendocrine tumors even though one of the FDA officials had questioned Novartis' findings on whether the drug was beneficial or not.


Novartis had narrowed down the benefits in its approval application before successfully presenting it to the FDA and is now looking forward towards a similar result in Europe after having filed applications with the European Medicines Agency and the Swiss regulator.

Stating that their drug was the first to be approved for the disease for more than three decades in the United States, Novartis released a statement saying, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin."

Source: Medindia

Recommended Reading

open close


Novartis Announces FDA Approval for Rare Pancreatic Cancer Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests